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Sj¨ ogren’s syndrome is an autoimmune disease characterized by an autoimmune exocrinopathy involving mainly salivary and
lacrimal glands. The histopathological hallmark is periductal lymphocytic inﬁltration of the exocrine glands, resulting in loss of
their secretory function. Several systemic manifestations may be found in patients with Sj¨ ogren’s syndrome including neurological
disorders. Neurological involvement ranges from 0 to 70% among various series and may present with central nervous system
and/or peripheral nervous system involvement. This paper endeavors to review the main clinical neurological manifestations in
Sj¨ ogren syndrome, the physiopathology, and their therapeutic response.
1. EpidemiologyofNeurologicalInvolvementin
Sj¨ ogren’s Syndrome
Sj¨ ogren’s syndrome (SS) is a common autoimmune dis-
ease (AID) characterized by an autoimmune exocrinopathy
[1] involving mainly salivary and lacrimal glands. The
histopathological hallmark is periductal lymphocityc inﬁl-
tration of the exocrine glands, resulting in loss of their
secretory function. This disease occurs alone as primary
SS (pSS), or in a background of connective tissue diseases
as secondary SS (sSS). Even though keratoconjunctivitis
sicca (resulting from the involvement of lacrimal glands)
and xerostomia (resulting from that of salivary glands) are
usually prominent, SS presents as a multifaceted condition
with a broad variety of clinical manifestations (i.e., fatigue,
arthralgias, Raynaud’s phenomenon, interstitial pneumo-
nias, lymphadenopathy, vasculitic urticaria, purpura, renal
tubular acidosis, and neurological involvement) and bio-
logical abnormalities of B lymphocytes manifests as hyper-
gammaglobulinemia; production of anti-SSA and anti-SSB
autoantibodies and of rheumatoid factor; and an increased
risk of non-Hodgkin’s B-cell lymphoma (NHL) [2, 3].
This polymorphism accounts for the delay in the diag-
nosis. As a consequence, there is very likelihood that the
prevalence of the disease is far higher than previously
estimated [4]. European Community Study Group on diag-
nostic criteria for SS (2002) is used to classify patients with
the disease [5].
Neurological involvement in SS may be manifested in
the central nervous system (CNS) and/or peripheral nervous
system(PNS).Theprevalenceofneurologicalmanifestations
ranges between 0 and 70% according to the investigators
and depending on the recruitments of their clinics, but in
general, such complications occur in about 20% of patients
[6–12]. This impressive heterogeneity may be explained
by the medical department where patients are recruited
(i.e., internal medicine versus neurology) [8], the diagnosis
criteria for pSS used (before 2002), or the deﬁnition of
speciﬁc neuropathies and the diagnostic test performed to
classify the neurological involvement (mainly in asymp-
tomatic patients). Notably, series published before year 2002
i n c l u d e ds o m ep a t i e n t sa sc o n s i d e r e da ss u ﬀering from pSS
without histology and/or antibody evidence. Comparison
between these series is impeded by the heterogeneity in the
diagnostic criteria.
To illustrate this concern, in a series by Laﬁtte et al.
[8], neurological manifestations in pSS were analyzed in
two cohorts from two medical departments (25 patients
from internal medicine and 11 patients from neurology
department). Neurological involvement was found in 40%2 Autoimmune Diseases
of patients from the internal medicine department. PNS
involvement was present in 4 of 25 patients from the internal
medicine group, whereas, in the neurology department,
there were 10 of 11 patients (mainly axonal sensorimo-
tor/sensory polyneuropathy). CNS involvement occurred in
7/25 patients from the internal medicine department and
4/11 from neurology. Cognitive dysfunction was the most
frequent CNS ﬁnding. Thus, these results conﬁrmed that
neurological involvement in SS varies according to medical
department where patients are evaluated.
Selection of patients in the diﬀerent series is other matter
of concern. Most of these series have been constructed retro-
spectively. For example, Mori et al. [11] reported 92 patients
evaluated by neurological symptoms, but the majority of
patients (93%) were diagnosed with pSS after neuropathy.
Patients were evaluated between 1985 and 2004. Thus, part
of patients was diagnosed with the criteria proposed by the
DiagnosticCommitteeofHealthandWelfareofJapan(1999)
[13]. On the other hand, Gøransson et al. [12] in a cross-
sectionalstudyevaluatedPNSin62pSSpatientsapplyingthe
American-Europeanclassiﬁcationcriteria.Inthisseries,27%
of patients presented neuropathy after clinical examination,
and 55% had abnormal conduction studies.
Neurologicalmanifestationsmayprecedethesiccasymp-
toms in 40 to 93% of the cases [8, 14]. As described by
Mori et al. [11], 93% of patients were diagnosed with pSS
after neuropathy symptoms appeared. Patients with pSS and
neurological involvement are older than patients without
neurological implication [9, 10].
pSS-associated neurological main manifestations are
listed in Table 1. PNS involvement in pSS is well character-
ized, manifested mainly as axonal polyneuropathies (sensory
and sensorimotor), trigeminal neuropathy, and small-ﬁber
neuropathy. Distal axonal sensory or sensorimotor polyneu-
ropathy accounts for over 50% of cases of PNS involvement
[6, 7, 15]. On the other hand, CNS manifestations are
heterogeneous, manifested as focal or diﬀuse involvement.
Most series reported that PNS involvement is more common
than CNS disease. However, Delalande et al. reported the
same frequency of central and peripheral nervous system
involvements [15].
Other aspect to analyze is the severity of evaluated
patients.Mostofthepreviousstudieshavebeenconductedat
reference centers, thus probably patients seen in these studies
have a more severe disease. Lopate et al. [16] showed the
prevalence of neuropathy in pSS in an outpatient setting. In
the outpatient context, they evaluated 22pSS patients and
10 controls for evidence of neuropathy. Isolated small-ﬁber
neuropathy was found in 45% of cases and none of con-
trols. Large-ﬁber dysfunction was similar between the two
groups. This study highlights the importance of subclinical
neuropathy present in many pSS patients that may lead to
disability related to painful distal paresthesias and also the
clinical diﬀerences according to the patient setting.
2.Pathophysiology
The pathogenic mechanisms responsible for most forms of
neurological involvement in pSS are unknown. To explain
Table 1: Neurological manifestations in primary Sj¨ ogren’s syn-
drome.
Peripheral disorders Central disorders
Axonal polyneuropathies
(i) Symmetric pure sensory
peripheral neuropathy
(ii) Symmetric sensorimotor
peripheral neuropathy
Focal
(i) Seizures
(ii) Movement disorders
(iii) Cerebellar syndrome
(iv) Optic neuropathies
(v) Pseudotumor lesions
(vi) Motor and sensory
loss
Sensory ganglioneuronopathy
Multifocal disease
(i) Cognitive impairment
(ii) Encephalopathy
(iii) Dementia
(iv) Psychiatric
abnormalities
(v) Aseptic
meningoencephalitis
Motor neuropathy
Spinal cord dysfunction
(i) Chronic progressive
myelopathy
(ii) Lower motor neuron
disease
(iii) Neurogenic bladder
(iv) Acute transverse
myelitis
Small-ﬁber neuropathy Progressive-multiple
sclerosis-like syndrome
Multiple mononeuritis Central nervous system
vasculitic involvement
Trigeminal and other cranial
nerves neuropathies
Autonomic neuropathies
Demyelinating
polyradiculoneuropathy
this involvement, many hypothesis have been considered.
Three pathogenic factors may explain the CNS disorders.
The ﬁrst hypothesis is the direct inﬁltration of the CNS by
mononuclearcells[17].Bakchinetal.[17]r epo rt edapatie nt
with ataxia, oculomotor paralysis, seizures, and a large lym-
phocytic inﬁltrate at postmortem examination. The second
hypothesis is the vascular involvement. The vascular injury
mayberelatedtothepresenceofantineuronalantibodiesand
anti-Ro antibodies [18]. Finally, Alexander [19–21]s u g g e s t
that the underlying mechanism of CNS lesion in pSS is the
ischemia secondary to small vessel vasculitis.
Severalmechanismsaresuggestedforthedevelopmentof
the involvement of PNS in pSS patients. Vascular or periph-
eralinﬂammatoryinﬁltrateswithorwithoutnecrosismaybe
found [14, 22]. Vasculitis of the vasa nervorum has also been
proposed as pathogenic mechanism in PNS involvement
[14]. However, others studies have not replicated these ﬁnd-
ings [15, 23]. In the case of motor neuropathy, necrotizingAutoimmune Diseases 3
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Figure 1: Pathophysiological mechanism implicated in the devel-
opment of central and peripheral nervous system manifestations in
primary Sj¨ ogren’s syndrome.
vasculitis may be found. Lymphocytic inﬁltration of the
dorsal ganglia has been found in some cases of sensory
neuronopathy [24]. Antineuronal antibodies have also been
described in patients with PNS involvement [25], but the
pathological role of these antibodies remains unknown.
Antibodies against the type 3 muscarinic receptor have also
been described in pSS. These antibodies have shown to be
functional, and they are able to inhibit neuron-mediated
contraction throughout the gastrointestinal tract. Thus,
these antibodies may eventually explain part of the broader
autonomic dysfunction found in pSS patients [26]. Figure 1
summarizes the main pathophysiological mechanisms.
3. Central Nervous System Involvement
CNS involvement has not been as well deﬁned as the PNS
involvement. Thus, CNS involvement in pSS is controversial,
and its prevalence ranges from 0% to 68% [15], according
to diﬀerent series [27–29]. Garc´ ıa-Carrasco et al. reported
only 1% of CNS involvement (4 patients in a cohort of
400pSS patients) [29]. SNC involvement varies from diﬀuse
compromise, manifested as cognitive deﬁcits or meningoen-
cephalitis, to focalized compromise, with spinal involvement
or optic myelitis. The diagnostic is more diﬃcult compared
to PNS involvement, due to unspeciﬁc symptoms.
Alexander et al. [18] described CNS manifestations in
20% of pSS patients. The same group [6] showed that
63% of patients presenting CNS involvement had PNS
manifestations.Escuderoetal.[30]reportedthatheadacheis
the main CNS complication in pSS. In addition, subclinical
tissue injury may be determined by magnetic resonance
imaging (MRI). This method also permits to determine the
extension and severity of CNS involvement [27, 31].
Due to high variation in clinical symptoms and signs
derived from CNS involvement, some authors propose that
these manifestations in pSS are a fortuity association and
the link between CNS manifestations and pSS is not well
characterized.
3.1. Focal Involvement. Focal encephalic involvement is the
mainCNSmanifestationinpSS[6,15].Thesefocaldisorders
can include motor and sensory loss with hemiparesis, apha-
sia, dysarthria, seizures, movement disorders, and cerebellar
syndrome. Their onset may be acute of insidious or even in a
recurring pattern that resembles to multiple sclerosis. Some
criteria such as older age, PNS or cranial nerve involvement,
spinal cord MRI lesions spanning multiple segments, and
cerebral MRI showed cortical brain lesions are characteristic
of pSS involvement and rarely seen in multiple sclerosis
[27, 28].
Spine cord disorders can include acute or chronic
progressive myelopathies, lower motor neuron disease, or
neurogenic bladder [15, 32, 33]. Spine complications may
be associated with encephalic involvement. In the series
by Laﬁtte et al. [8], myelopathies are reported in 3 of 11
patients with SNC involvement. The clinical picture is often
characterized by transverse myelitis [32–34]. Although rare
in pSS, acute and chronic myelopathies are frequently severe
and life-threatening. These manifestations usually respond
poorly to treatment with corticosteroids. Immunosuppres-
sive treatment with cyclophosphamide and steroids has
shown some eﬃcacy in patients with progressive disease (see
Section 7).
Subacute transverse myelitis with high signal on T2
weighted images and abnormal cerebrospinal ﬂuid (CSF)
study (increased protein level and cell count) is a rare but
well-described complication in pSS patients [35, 36].
Optic neuropathies have been also described in pSS [37].
This manifestation can be asymptomatic. Alexander [38]
reported seven cases of retrobulbar optic neuropathy in pSS
patients. Four asymptomatic patients were diagnosed by
visual evoked potentials.
Sanahuja et al. [31] described a case of a pSS patient
with a large tumefactive brain lesion, who responded well
to oral corticosteroid treatment. This lesion, although rarely
reported, has to be considered in pSS patients. Diﬀerential
diagnosis includes lymphoma, glioma, abscesses, metastasis,
progressive multifocal leukoencephalopathy, and dissemi-
nated encephalomyelitis.
3.2. Diﬀuse Involvement. CNS involvement can be diﬀuse,
presenting encephalopathy, cognitive disfunction, dementia,
psychiatric abnormalities, and aseptic meningoencephalitis
[39–41]. This last complication is characterized by abnormal
CSF, with lymphocytic cells and proteins.
Cognitive disturbances of variable severity have been
described in pSS patients without mood disorders [8].
Laﬁtte el al. reported 8 from 36pSS patients with cognitive
dysfunction, characterized by frontal executive dysfunction,
impairment in attention control, intellectual decline, and
deterioration of instrumental abilities. Cognitive impart-
ment is not correlated with CSF abnormalities or MRI
ﬁndings[42,43].Malinowetal.[44]described25psychiatric4 Autoimmune Diseases
abnormalities in 40pSS patients. Of 16 patients undergoing
cognitive function testing, 7 presented mild memory impair-
ment with attention and concentration deﬁcits. Belin et al.
[45] evaluated 14pSS patients with brain MRI, brain 99m
Tc-SPECT, and neuropsychological testing. In this series, all
patients presented neuropsychological abnormalities, mostly
frontallobesyndromeandmemoryproblems.Theneurolog-
ical involvement was associated with SPECT abnormalities,
but not MRI imaging results. Ferreiro et al. reported a
patient with diﬀuse angiographic changes, supporting that
an ischemic mechanism caused by CNS vasculitis may be
responsible for the clinical presentation in some patients
[46].
In conclusion, these studies show the wide range of CNS
manifestations that could be associated with pSS. Also, it
is important to recognize cognitive problems, which are
common in pSS, and cognitive evaluation is a sensible tool
sensible to diagnose CNS compromise.
4. Peripheral Nervous SystemInvolvement
As described in epidemiology section, peripheral neuropathy
isthemostcommonneurologicalcomplicationofpSS.Itcan
be present between 20 and 50% of patients when subclinical
neuropathy is revealed by a systematic electrophysiological
study [47] and clinically from 10 to 32% [6, 14]. In 1962,
Kaltreider and Talal [22], described for the ﬁrst time, the
prevalence of neurological involvement in pSS. In this series,
8.3% (n = 9) of 109 patients presented neuropathies.
PNS disease includes axonal polyneuropathies (dis-
tal axonal sensory and sensorimotor), neuronopathies,
mononeuropathies, cranial nerves involvement (mainly
trigeminal neuropathy), and autonomic system involvement
(Table 1). Axonal polyneuropathies are the most common
manifestations of PNS involvement found in 50% of PNS
cases [14, 15].
In the series by Gøransson et al. [12], 27% of patients
presented peripheral neuropathy and nerve conduction
studies were indicative of motor neuropathy in 31% of cases.
4.1. Axonal Polyneuropathies. T h ea x o n a lp o l y n e u r o p a t h i e s
are the most frequent clinical presentation of PNS involve-
ment in pSS. It includes distal sensorimotor and sensory
polyneuropathies. Clinical manifestations usually start with
distal and symmetric sensitive involvement. Large-ﬁber sen-
sory dysfunction is evidenced by electrodiagnostic studies.
4.1.1. Sensory Polyneuropathy. Distal sensory polyneuropa-
thy is the most characteristic peripheral involvement in
pSS [48]. Sensory neuropathy is characterized clinically by
sensitive signs on the lemniscal way, with prevalence on the
lower limbs. Manifestations include distal paresthesias and
evidence of large-ﬁber sensory dysfunction on examination
and electrophysiological studies. In the series described by
Mellgren et al. [14], 33pSS patients with neuropathy were
evaluated for neurological examinations, electromyography,
and nerve conduction studies. Evaluation also included sural
nerve biopsy in 11 patients. Thirty-two percent presented
exclusive sensory neuropathy. Mori et al. [11]d e s c r i b e d
18 patients with painful sensory neuropathy and 36 with
sensory ataxic neuropathy from one series of 92pSS with
neuropathy, conﬁrming its high prevalence. This manifes-
tation may be related to skin vasculitis but regularly is not
associated with other systemic manifestations of pSS.
4.1.2. Sensorimotor and Motor Polyneuropathy. A mixed sen-
sorimotor polyneuropathy, involving large diameter ﬁbers,
most commonly axonal, may be present in pSS. The
motor neuron involvement (amyotrophic lateral sclerosis
syndromeandanteriorhornsyndrome)isarareneurological
manifestation in pSS [49] and may be associated with CNS
involvement [50].
Another manifestation is the acute motor axonal neu-
ropathy (AMAN), a variant seen in nearly 5% of Guillain-
Barr´ e syndrome. More than 60% of AMAN patients have
antibodies against ganglioside M1 (GM1) [51, 52]. One case
described by Awad et al. [53] showed a patient who devel-
oped rapidly fulminant AMAN with anti-GM1 antibodies.
Anti-SSA antibodies were also elevated, and sialadenitis
was evidenced by minor salivary gland biopsy. This patient
responded dramatically to intravenous immunoglobulin
(IVIg) treatment.
4.2. Sensory Ganglioneuronopathy. Sensory ganglioneu-
ronopathy or sensory ataxic neuropathy produced by
posterior spinal roots involvement is manifested as sensory
ataxia, and it is characterized by severe impairment of
kinaesthetic sensation with no obvious motor involvement
[54]. This type of neuropathy may be considered as a
subgroup of sensory neuropathy. Physiopathology is
probably due to lymphocytic inﬁltrates on posterior roots
and spinal ganglions [11, 24, 54]. In these studies, it has
been described lymphocytic inﬁltrates without vasculitis
and degeneration of dorsal root ganglion neuronal cell
bodies. Some authors also propose a role of autoantibodies
in this manifestation. Among nine patients with pure
sensory neuropathy in the study by Delalande [15], four
presented clinical and electrophysiological features of
sensory ganglioneuronopathy with ataxia. This form
of neuropathy is chronic and progressive, occasionally
responding to treatment with IVIg [55].
4.3. Small-Fiber Neuropathy. Special mention requires the
more recent described small-ﬁber neuropathy in pSS. About
40% of pSS patients experience chronic neuropathic pain
with normal electrodiagnostic studies [56–60]. In these
cases, quantiﬁcation of epidermal nerve ﬁber density in
skin biopsy has been validated as a diagnostic tool of small
ﬁber neuropathy [61]. In the biopsy, the intraepidermal
nerve ﬁber density is calculated. In the article published by
Fauchais et al. [60], 14pSSs with chronic neuropathic pain
and normal neurological examination were evaluated. Small
ﬁber neuropathy was conﬁrmed by skin biopsy in 13/14
cases. Clinical manifestations were mainly distal burning
sensation, dysesthesia, prickling, and allodynia, localized in
both hands and feet.Autoimmune Diseases 5
In the outpatient cohort described by Lopate et al.
[16], 50% of patients with pSS complained of painful distal
paresthesias with evidence of small-ﬁber sensory loss with
normal large-ﬁber function. Most part of these patients has
not been diagnosed before, showing that subclinical or mild
neuropathy may be present in pSS and can eventually lead to
disability.
The physiopathological mechanism is not well studied.
Ischemic and vasculitis processes have been implicated in the
small-ﬁber lesions [62]. Proinﬂammatory cytokines, such as
tumor necrosis alpha (TNF-α), have been also implicated,
and some clinical improvement has seen with IVIg therapy
[63] and anti-TNF-α [64] in other clinical conditions.
Some reports showed that patients who initially pre-
sented with a small-ﬁber neuropathy later developed a
sensory ataxic neuropathy [11], suggesting that small-ﬁber
neuropathy is on a continuum with large-ﬁber sensory
neuropathy.
4.4. Multiple Mononeuropathy. Similar to multiple mono-
neuropathy in the context of other AID, this complication
is rarely seen in pSS [9, 14]. In the series by Mori el al.
[11],11of92patientswithpSS-associatedneuropathy(12%)
were classiﬁed with multiple mononeuropathy. Their clinical
evolution is generally faster and more invaliding in pSS
compared to other diseases. This complication is associ-
ated with cutaneous vasculitis and cryoglobulinemia. The
multiple mononeuropathy is mainly produced by ischemic
mechanisms [65].
4.5. Trigeminal and Cranial Nerves Neuropathies. Often mul-
tiple and recurrent cranial nerves neuropathy may be present
in pSS. The most common is trigeminal neuropathy, fol-
lowed by facial and oculomotor nerves involvement [66, 67].
This trigeminal neuropathy presents sensory rather motor
involvement. It involves generally the inferior branch of the
trigeminal nerve and remains usually clinically unilateral.
Tajima et al. [68] reported the prevalence of trigeminal
involvement as high as 50% of patients with cranial nerves
compromise. Mori et al. found that 15 of 92 patients (16%)
had trigeminal neuropathy with sensory impairment [11].
None presented motor trigeminal involvement. In Delalande
serie [15], coclear-vestibular nerve involvement seems to
be more frequent (35% of cranial nerve involvement) than
trigeminal neuropathy (29%).
4.6. Autonomic Neuropathy. In some patients, autonomic
neuropathymaybemanifestedwithAdie’spupils,anhidrosis,
ﬁxed tachycardia, and orthostatic hypotension [9, 11, 16,
69]. Autonomic symptoms may be explained by both
ganglioneuronopathy and vasculitis. Mellgren et al. [14]
reported autonomic neuropathy in 6 of 33 patients with pSS
(18%). In the series by Andonopoulos et al. [70], autonomic
involvement was routinely searched in 32 patients with pSS.
Fifty percent of patients presented autonomic symptoms
induced by clinical tests. Most of cases have been reported to
be mild [71]. Mori et al. reported 3 of 92 patients with sever
autonomic neuropathy [11]. Adie’s pupil, associated with
autonomic involvement in pSS [72], is presumably caused
by neuronitis in the ciliary ganglion cells. Antibodies against
acetylcholine receptor have been described in patients with
pSS and autonomic symptoms [73].
However, other studies have not shown the increased
involvement of autonomic system compared to controls.
Niemel¨ a et al. [74] performed a complete evaluation of
autonomic functions on 30pSS patients and 30 controls.
They showed no diﬀerences between the two groups in any
of the test, concluding that the prevalence of autonomic
dysfunction in pSS is similar to general population.
4.7. Polyradiculoneuropathy. Acute of chronic polyradicu-
loneuropathies have been described in patients with pSS
[10, 11]. However, the prevalence in pSS seems to be similar
in the clinical, physiopathological, and anatomic context to
idiopathic polyradiculoneuropathies.
5.Diagnosticof Neurological
Involvement in pSS
5.1. Cerebrospinal Fluid. CSF may be useful to classify
some manifestations. Lymphocytes may be found in some
manifestationsusuallylessof50cells/mm3.Inasepticmenin-
goencephalitis, CSF is abnormal with a higher number of
lymphocytes, increased level of proteins, and intrathecal
synthesis of gamma globulins [75]. The IgG index is
increased during periods of disease activity in up to 50% of
cases. CSF is also necessary to the diﬀerential diagnosis (i.e.,
infection, multiple sclerosis). Oligoclonal bands (speciﬁcally
more than three bands) are highly speciﬁc of multiple
sclerosis diagnosis. These bands have been reported in about
20to25%ofpSScomparedtomorethan90%inMSpatients
[76–78]. The oligoclonal bands are not stable during the
course of the pSS and can disappear after treatment with
steroids.
5.2. Magnetic Resonance Imaging. MRI abnormalities are
common in pSS and usually consist in hyperintense areas
in the subcortical and periventricular white matter on T2-
weighted and ﬂuid-attenuated inversion recovery (FLAIR)
sequences [27, 28]. These lesions are usually less pronounced
in pSS than in patients with multiple sclerosis and rarely
touch the basal ganglia or the cerebral cortex.
5.3. Nerve Conduction Velocity Studies. Motor and sensory
nerve conduction velocity studies are tested in the median,
tibial, and sural nerve. These values give characteristic
patterns about the speciﬁc neuropathy, and they can dif-
ferentiate the two major types: axonal degeneration and
demyelinating. Axonal polyneuropathy is the most frequent
pattern seen in pSS PNS involvement.
5.4. Electromyography. Electromyography patterns such as
action potential amplitude twice to normal and an increase
in duration of action potential may help to diﬀerentiate the
neuropathies from myopathies. In pSS, electromyography
shows a typical pattern of axonal polyneuropathy, with6 Autoimmune Diseases
diminution of sensory amplitudes without latency or con-
duction velocity involvement. Asymptomatic neuropathies
can be found by systematic electromyography test [7].
5.5. Sural Nerve Biopsy. Most of the nerve studies in pSS
patients with neuropathy have been performed on sural
nerve. Mellgren et al. [14] reported vascular or perivascular
inﬂammation of small epineurial vessels in 11 patients with
pSS-related neuropathy. In two patients, a necrotizing vas-
culitis was diagnosed. In this study, axonal degeneration was
observed in both sensorimotor and sensory neuropathies.
In the study by Griﬃn et al. [54], most of 12 biopsies
showed varying degrees of myelinated ﬁber loss. Six biopsies
had inﬂammatory inﬁltrates around epineurial vessels, but
necrotizing vasculitis was not evidenced. Cases of multiple
mononeuropathy have shown vasculitis in small arteries and
arterioles.
5.6. Skin Biopsy. Utility of skin biopsy in the diagnosis of
pSS-related neuropathy has been described in the section of
small-ﬁber neuropathy.
5.7. Neuromuscular Biopsy. The utility of neuromuscu-
lar biopsy in pSS-related neuropathy has been evaluated
[79]. In the study by Terrier et al., 40pSS patients with
neuropathy underwent neuromuscular biopsy. Pathological
results (necrotizing vasculitis in 14 patients and lymphocytic
vasculitis in 8) were associated with acute-onset neuropathy,
multiple mononeuropathy, and sensorimotor involvement,
compared to 18 patients without vasculitis on the neu-
romuscular biopsy. Necrotizing vasculitis was signiﬁcantly
associated with a better outcome and response to immuno-
suppressive treatment.
5.8. Autonomic Neuropathy Tests. To classify patients with
autonomic neuropathy, diﬀerent test such as Till-table
test, gastrointestinal test, thermoregulatory sweat test, or
quantitative sudomotor axon reﬂex test may be used.
6.Biological Markers in Patients with pSS and
Neurological Manifestations
Anti-Ro and anti-La seem to be less frequent in pSS
patients with neurological involvement (40%) compared
to patients without neurological manifestations (60% of
positivity). Thus, new markers are necessary in pSS to
better classify subpopulations of patients with neurologi-
cal involvement. Some antibodies have been described as
potential serological markers of neurological involvement
in pSS. However, their useful application is doubtful. IgA
and/or IgG anti-alpha-fodrin antibodies in pSS appear to be
common in neurological pSS (64.5% of 31pSS patients with
neurological manifestations) [80]. However, this percentage
was not diﬀerent from pSS patients without neurological
manifestations. Giordano et al. [81]e v a l u a t e dI g Ma n dI g G
anti-GM1 in 30pSS patients and its relation with peripheral
neuropathy.Anti-GM1antibodieswerepresentin12patients
(6 with neuropathy and 6 without), thus showing little
help to classify pSS patients with peripheral neuropathy.
Antineuronal antibodies have also been described in pSS
[82], although their pathological role is unknown.
Anti-GW182 antibodies directed against GW182 protein
(a protein located in cytoplasmic structures called GW
bodies) have been characterized in autoimmune diseases
(mainly in pSS) [83]. In this group, 18 sera of 200 patients
(9%) with autoimmune diseases were positive for anti-
GW182antibodies.Interestingly,positivepatientshadmixed
motor and/or sensory neuropathy (n = 9), pSS with neu-
rological symptoms (n = 3), and 6 patients presented SLE
or pSS without neurological manifestations. In conclusion,
anti-GW182 antibodies may help to classify patients with
autoimmune neurological involvement in diﬀerent AID.
Of special interest, the antitype 3 muscarinic receptor
antibodies have been described in pSS. The IgA isotype may
be involved in the pathogenesis of autonomic dysfunction
and also may be useful as a novel marker in the pSS diagnosis
[84]. Their utility to discriminate patients with neurological
involvement has to be tested. Table 2 summarizes the anti-
bodies in neurological manifestations in pSS patients.
Some other biological markers have been described in
neurological involvement in pSS. Among these markers,
patients with sensorimotor neuropathy have higher rates of
mixed cryoglobulin compared to pSS without neurological
manifestations (57% versus 11%), monoclonal gammapathy
(71% versus 17%), and NHL (57% versus 3%). On the
other hand, patients with sensory neuropathy show lower
prevalence of chronic B-cell activation markers (lower
prevalence of antinuclear antibodies, anti-SSA, and anti-
SSB) [85]. Therefore, these results demonstrate that the
pathophysiological mechanism is diﬀerent according to
polyneuropathy type, and the B-cell activation markers can
be useful to classify a number of patients with a more severe
diseaseandriskoflymphoproliferation, accompanyingsome
neurological manifestations.
7. Treatment of Neurological Manifestations in
Sj¨ ogren’s Syndrome
There is no consensus about the speciﬁc treatment of
neurological involvement in pSS. Generally, corticosteroid
therapy is initiated in patients with either CNS or PNS
[15, 86]. CNS involvement is usually treated with high
corticosteroid dose. In some cases, response to treatment
is exceptional. For example, Caselli et al. [87] showed one
patient with dementia who markedly improved after corti-
costeroid treatment. Concerning the treatment of acute and
chronicmyelopathies,deSezeetal.[88]showedthetolerance
and clinical response of a combination regimen of steroids
and monthly cyclophosphamide. Fourteen patients (6 with
acute and 8 with chronic myelopathies) were evaluated.
Tolerance was good, and nine patients improved clinically
(including the total 6 patients with acute myelopathy), three
patients remained stable, and the other two patients pre-
sented moderate progression. Although randomized studies
are necessary, this treatment needs to be considered in
patients with progressive disease.Autoimmune Diseases 7
Table 2: Antibodies in neurological manifestations of primary Sj¨ ogren’s syndrome.
Antibody Clinical association Reference
Anti-SSA and anti-SSB
Most of studies show lower prevalence of anti-SSA and
anti-SSB antibodies in pSS with neurological
involvement. In one series, patients with nonataxic
sensory neuropathy had lower prevalence of anti-SSA
(40% versus 72%) and anti-SSB (15% versus 41%).
Sene et al. [85]
Anti-SSA
This paper showed that anti-Ro antibodies were
positive in 48% of patients with CNS compared to only
24% of all patients with pSS. However, the anti-SSA
antibodies were detected by double immunodiﬀusion
and not by ELISA.
Alexander et al. [18]
Anti-alpha fodrin (IgA and IgG)
These antibodies are common patients in pSS.
However, there are not diﬀerences between patients
with or without clinical neurological involvement.
De Seze et al. [88]
Anti-GM1 (IgM and IgG) No diﬀerences between pSS patients with or without
neurological involvement. Giordano et al. [81]
Antineuronal antibodies
In a large series of patients with neurological disorders
(n = 882), these antibodies were detected in patients
with pSS and neurological involvement, although the
speciﬁcity has to be deﬁned. Antiganglion neuron
antibodies have been also reported.
Murata et al. [25],
Vianello et al. [82]
Anti-GW182
Detected in patients with mixed motor and/or sensory
neuropathy without pSS and also in neurological
involvement in pSS patients.
Eystathioy et al. [83]
GM1: ganglioside; GW182: protein located in cytoplasmic structures called GW bodies; CNS: central nervous system; pSS: primary Sj¨ ogren syndrome.
Classically, peripheral neuropathy in patients with pSS
responds poorly to treatment [11, 15, 86]. Some groups
recommend only treating the symptoms according to the
severity.Inotherpatients,immunosuppressivetherapybased
on corticosteroids, cyclophosphamide, azathioprine, and
even plasmapheresis has shown only mild success [89–91].
In the series reported by Terrier et al. [79], patients with
necrotizing vasculitis have a better response to immunosup-
pressive treatment, mainly with cyclophosphamide (71% of
patients with necrotizing vasculitis showed good response
compared to 25% of patients with lymphocytic vasculitis).
Griﬃn et al. reported a treatment based on corticosteroids
and associated in some cases with azathioprine, intravenous
cyclophosphamide or plasma exchanges [54]. Only one
patient with a relapsing course responded to corticosteroid
treatment. Mori et al. suggested that corticosteroids are
suitable for multiple neuropathy and multiple cranial neu-
ropathy [11].
IVIg has been also reported as a good therapeutic option
in some painful sensory neuropathy cases [92] and in
radiculoneuropathy. In a recently series of 19pSS patients
with peripheral neuropathy, intravenous immunoglobulin
treatment was evaluated [93]. In this study, 8 patients
(42%) showed a decrease of the disability Modiﬁed Rankin
Scale, corresponding to a clinical improvement. Patients
with sensorimotor or nonataxic sensory neuropathy were
markedly improved compared to patients with ataxic neu-
ropathy (2/9). The authors concluded that clinical ben-
eﬁts of IVIg treatment depend on the speciﬁc clinical
subtype.
Caroyer et al. [94] showed improvement in sensory
ganglioneuronopathy treated with inﬂiximab. However, no
controlled trials have shown eﬃcacy of inﬂiximab or others
anti-TNFα in pSS-related neuropathy.
Rituximab, an anti-CD20 antibody, may be useful in
systemic complications in pSS patients [95, 96] and in
some cases of refractory neuropathy. Recently, Mekinian
et al. [97] reported 17 patients with pSS and PNS involve-
ment treated with rituximab. Neurological improvement
was observed in 11/17 patients (65%) at three months.
Best results were observed in patients with cryoglobuline-
mia or vasculitis-related PNS involvement (9/10 patients
improved).
The beneﬁts from treatment with oromucosal IFN-α
in pSS have been reported by several groups [98–101].
Due to possible eﬀects on sicca symptoms, Yamada et al.
[102] reported three cases of pSS-associated neuropathy
treated with oral IFN-α (two patients with sensory ataxic
neuronopathy and one patient with axonal sensorimotor
neuropathy with demyelinating features). All three patients
responded well to IFN-α, improving the neurological symp-
toms. Sicca symptoms, antibodies titres, and focus score
of salivary gland biopsy were also improved. However, the
mechanisms whereby IFN-α induces neurological improve-
ment in pSS are uncertain.
In conclusion, neurological manifestations are common
in pSS and often precede the diagnosis. The accurate preva-
lence of these manifestations is diﬃcult to assess, because
the heterogeneity of the series. The pathogenic mechanisms
responsible for most forms of neurological involvement in8 Autoimmune Diseases
pSS remain unknown, but vascular, ischemic, and immuno-
logical mechanisms have been described. Controlled and
population-based trials are necessary to better characterize
the neurological manifestations in pSS and their therapeutic
response.
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